Monday, June 15, 2026

South Korea Surpasses 2 Million Medical Tourists in 2025, with Double Visa-Free Chinese Visitors

South Korea welcomed over 2 million foreign patients in 2025, driven by a visa-free policy for Chinese tourists and high demand for medical services.

A 21st-Century Gestapo? Kim Jong Un’s New Police State

North Korea plans to establish a police system, aiming to refine its security framework, though true implications remain uncertain.

LG Display Unveils 40-inch P2P Display for Next-Gen Vehicles

LG Display unveils a 40-inch Pillar-to-Pillar display for vehicles, enhancing SDV functionality with advanced infotainment and safety features.

Tag: GLP-1

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

AstraZeneca’s Elecoglipron: Can This New Weight Loss Pill Compete with GLP-1 Giants?

AstraZeneca's new weight-loss pill, elecoglipron, shows promising results in trials, competing with existing obesity treatments.

Wegovy Breaks Records: 3 Million Prescriptions in Just 5 Months – What You Need to Know

Wegovy surpasses 3 million prescriptions in 5 months, marking a significant milestone in the U.S. obesity treatment market.

Wegovy, Mounjaro Boom Creates New Winners as Ursa, InBody Ride GLP-1 Ripple Effects

GLP-1 obesity drugs are boosting gallstone prevention therapies and body composition monitoring, creating new market opportunities.

Samsung Launches GLP-1 Muscle Loss Study With Galaxy Watch8 and Harvard-Linked Hospital

Samsung is researching muscle loss management for GLP-1 drug users, led by the Galaxy Watch 8.

Celltrion Moves CT-G32 Into Final Preclinical Stage as Global Obesity Trial Preparation Accelerates

Celltrion advances CT-G32, a next-gen obesity treatment, targeting multiple pathways to enhance weight loss while preserving muscle mass.

MetaVia to Present DA-1726 Phase 1 Obesity Trial Data at EASL Congress 2026

Dong-A ST's Meta via will present DA-1726, a dual-action obesity treatment, at the EASL Congress 2026, showcasing promising clinical trial results.

Novo Nordisk’s Oral Wegovy Just Put Up a Number That Could Change the Obesity Drug Race

Novo Nordisk's oral obesity treatment, Wegovy, saw $400M in Q1 2026 sales, exceeding estimates and indicating strong market demand.

Unlocking Weight Loss: How GB102 Probiotics Enhance GLP-1 Obesity Drugs

GI Longevity's GB102 probiotic enhances weight loss with GLP-1 medications, reducing rebound gain and improving blood sugar control.

Metabia Begins Dosing First Patient in Phase 1 Part 3 Trial of Obesity Drug DA-1726

Metabia begins Phase 1 trial for DA-1726, a dual-action obesity treatment, aiming for safety and efficacy in weight loss by 2026.

Eli Lilly’s New Weight Loss Pill Foundayo: A Game Changer in the GLP-1 Market?

The FDA has approved Eli Lilly's oral obesity drug Foundayo, enhancing competition in the weight loss market with flexible dosing.

DA-1726: The New Dual-Action Obesity Treatment Set to Transform Weight Loss in 2026

MetaVia's DA-1726 obesity treatment trial approved by U.S. IRB, focusing on dual-action GLP-1 and Glucagon receptors for weight loss.

GLP-1 Weight Loss Injections: Are They Causing Gallstone Surge in Asia?

GLP-1 obesity treatments are linked to increased gallstone risk, especially during rapid weight loss, with cases doubling in South Korea.

Novo Nordisk Slashes GLP-1 Drug Prices by Up to 50%: What This Means for Obesity Treatments in 2027

Novo Nordisk will cut prices of GLP-1 treatments in the U.S. by up to 50% from January 2027, amid rising competition and market pressures.

Unlocking Weight Loss: How Celltrion’s New CT-G32 and Oral Multi-Action Drug Will Change the Game

Celltrion aims to lead the obesity treatment market with innovative drugs, enhancing efficacy and patient convenience through dual approaches.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.